Table 6  Determinants of health-related quality of life (EQ-5D) for patients who initiated b/tsdmard at baseline or follow-up.

From: Sociodemographic factors and biologic therapy exposure impacting health-related quality of life in psoriatic arthritis - findings from a nationwide registry Reuma.pt

 

Multivariable analyses

n = 102*

 

β

CI 95%

p -value

Time

−0.001

[−0.036; 0.034]

0.961

Employment status (non-employed)

−0.112

[−0.205; −0.019]

0.018

Married (yes)

   

Age of diagnosis (years)

−0.005

[−0.009; −0.001]

0.017

Disease phenotype (predominantly peripheral)

   

DAPSA

−0.004

[−0.007; −0.002]

< 0.001

Number of b/tsDMARD during follow-up

   

1 (reference)

   

2

   

3 or more

   

b/tsDMARDS therapy changes

   

Constant (reference)

   

Cycling

−0.186

[−0.313; −0.060]

0.004

Switching

−0.197

[−0.311; −0.082]

< 0.001

  1. *patients with complete data at baseline. EQ-5D – EuroQol five Dimensions; β - β coefficient; CI 95% - confidence interval 95%; ASDAS - Ankylosing Spondylitis Disease Activity Score; b/tsDMARDs – biologic or target synthetic Disease-Modifying Anti-Rheumatic Drugs.
Back to article page